Home Journals Books For Authors and Reviewers Online Submission News About Us Contact Us
Search
magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Online: 2575-7970 ISSN Print: 2575-7989 CODEN: IJCEMH
Frequency: bimonthly Email: ijcemr@hillpublisher.com
Total View: 2439485 Downloads: 547761 Citations: 244 (From Dimensions)
Search articles within this journal Submit an article

Journal Menu

Volumes & Issues

Current Issue

All Volumes

Download PDF

How to cite this paper

3760

TOTAL VIEWS

More Articles

ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2023.04.011

Research Progress on the Role of miRNAs in the Development of Gastric Cancer

Wenjun Jiang1,*, Ya Li2

1Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China.

2Clinical Laboratory Center of Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi, China.

*Corresponding author: Wenjun Jiang

Published: June 2,2023

Abstract

Gastric cancer is one of the most common malignant tumors in the world, with poor prognosis and is the main cause of cancer-related death. The 5-year survival rate of early gastric cancer can reach 90%. However, due to the low diagnosis rate of early gastric cancer, most patients are diagnosed as advanced gastric cancer at the first visit. Therefore, in order to improve the survival rate of gastric cancer patients, early diagnosis is particularly important. At present, tumor serum markers such as carcinoembryonic antigen (CEA), antibodies to Helicobacter pylori, histopathology, endoscopy, and determination of digestiogen are the main methods for the diagnosis and evaluation of gastric cancer. However, the effectiveness and sensitivity of these methods in the diagnosis of early gastric cancer are low. Therefore, it is of great significance to find new biomarkers with higher sensitivity and specificity for early diagnosis of gastric cancer. MiRNAs are abnormally expressed in many cancers, and some miRNAs are closely related to tumor development, progression and treatment. Therefore, miRNAs may be used as biomarkers for early diagnosis and prognosis of cancer in the future. In this review, the authors summarized the research progress of miRNAs in the development, early diagnosis and prognosis of gastric cancer, in order to provide new ideas for the future clinical treatment of gastric cancer.

Keywords

Gastric cancer, MiRNAs, Biomarker, Gene targets

References

[1] C. Mattiuzzi, G. Lippi, Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD), Eur J Public Health, 30 (2020) 1026-1027.

[2] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68 (2018) 394-424.

[3] W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015, CA Cancer J Clin, 66 (2016) 115-132.

[4] B. Song, J. Ju, Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis, Expert Rev Mol Med, 12 (2010) e33.

[5] W.K. Wu, C.W. Lee, C.H. Cho, D. Fan, K. Wu, J. Yu, J.J. Sung, MicroRNA dysregulation in gastric cancer: a new player enters the game, Oncogene, 29 (2010) 5761-5771.

[6] A.C. Cadamuro, A.F. Rossi, N.M. Maniezzo, A.E. Silva, Helicobacter pylori infection: host immune response, implications on 

[7] T. Ueda, S. Volinia, H. Okumura, M. Shimizu, C. Taccioli, S. Rossi, H. Alder, C.G. Liu, N. Oue, W. Yasui, K. Yoshida, H. Sasaki, S. Nomura, Y. Seto, M. Kaminishi, G.A. Calin, C.M. Croce, Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis, Lancet Oncol, 11 (2010) 136-146.

[8] M. Tsujiura, D. Ichikawa, S. Komatsu, A. Shiozaki, H. Takeshita, T. Kosuga, H. Konishi, R. Morimura, K. Deguchi, H. Fujiwara, K. Okamoto, E. Otsuji, Circulating microRNAs in plasma of patients with gastric cancers, Br J Cancer, 102 (2010) 1174-1179.

[9] H. Zhou, J.M. Guo, Y.R. Lou, X.J. Zhang, F.D. Zhong, Z. Jiang, J. Cheng, B.X. Xiao, Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker, J Mol Med (Berl), 88 (2010) 709-717.

[10] S. Cohen, MicroRNAs in animal development. Editorial, Semin Cell Dev Biol, 21 (2010) 727.

[11] R.C. Friedman, K.K. Farh, C.B. Burge, D.P. Bartel, Most mammalian mRNAs are conserved targets of microRNAs, Genome Res, 19 (2009) 92-105.

[12] Y. Lee, K. Jeon, J.T. Lee, S. Kim, V.N. Kim, MicroRNA maturation: stepwise processing and subcellular localization, Embo j, 21 (2002) 4663-4670.

[13] Y. Lee, M. Kim, J. Han, K.H. Yeom, S. Lee, S.H. Baek, V.N. Kim, MicroRNA genes are transcribed by RNA polymerase II, Embo j, 23 (2004) 4051-4060.

[14] J. Han, Y. Lee, K.H. Yeom, Y.K. Kim, H. Jin, V.N. Kim, The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev, 18 (2004) 3016-3027.

[15] W.M. Merritt, Y.G. Lin, L.Y. Han, A.A. Kamat, W.A. Spannuth, R. Schmandt, D. Urbauer, L.A. Pennacchio, J.F. Cheng, A.M. Nick, M.T. Deavers, A. Mourad-Zeidan, H. Wang, P. Mueller, M.E. Lenburg, J.W. Gray, S. Mok, M.J. Birrer, G. Lopez-Berestein, R.L. Coleman, M. Bar-Eli, A.K. Sood, Dicer, Drosha, and outcomes in patients with ovarian cancer, N Engl J Med, 359 (2008) 2641-2650.

[16] L.A. Macfarlane, P.R. Murphy, MicroRNA: Biogenesis, Function and Role in Cancer, Curr Genomics, 11 (2010) 537-561.

[17] B. Zhang, X. Pan, G.P. Cobb, T.A. Anderson, microRNAs as oncogenes and tumor suppressors, Dev Biol, 302 (2007) 1-12.

[18] T. Frixa, S. Donzelli, G. Blandino, Oncogenic MicroRNAs: Key Players in Malignant Transformation, Cancers (Basel), 7 (2015) 2466-2485.

[19] J. Hayes, P.P. Peruzzi, S. Lawler, MicroRNAs in cancer: biomarkers, functions and therapy, Trends Mol Med, 20 (2014) 460-469.

[20] M.V. Iorio, C.M. Croce, MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review, EMBO Mol Med, 4 (2012) 143-159.

[21] M.D. Jansson, A.H. Lund, MicroRNA and cancer, Mol Oncol, 6 (2012) 590-610.

[22] Y. Peng, C.M. Croce, The role of MicroRNAs in human cancer, Signal Transduct Target Ther, 1 (2016) 15004.

[23] A. Ventura, T. Jacks, MicroRNAs and cancer: short RNAs go a long way, Cell, 136 (2009) 586-591.

[24] X. Hou, M. Zhang, H. Qiao, Diagnostic significance of miR-106a in gastric cancer, Int J Clin Exp Pathol, 8 (2015) 13096-13101.

[25] J. Chen, C. Zhou, J. Li, X. Xiang, L. Zhang, J. Deng, J. Xiong, miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3, Int J Mol Med, 41 (2018) 1855-1866.

[26] J. Shen, W. Niu, H. Zhang, M. Jun, H. Zhang, Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN, Oncol Res, 26 (2018) 901-911.

[27] Z. Zheng, J. Li, J. An, Y. Feng, L. Wang, High miR-324-5p expression predicts unfavorable prognosis of gastric cancer and facilitates tumor progression in tumor cells, DiagnPathol, 16 (2021) 5.

[28] Y. Gu, Z. Fei, R. Zhu, miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway, Anticancer Drugs, 31 (2020) 385-393.

[29] Q. Ni, Y. Zhang, R. Tao, X. Li, J. Zhu, MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling, Aging (Albany NY), 13 (2021) 8665-8687.

[30] R. Yan, K. Li, D.W. Yuan, H.N. Wang, Y. Zhang, C.X. Dang, K. Zhu, Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1, Int J Oncol, 53 (2018) 2566-2578.

[31] P. Wang, Z. Li, H. Liu, D. Zhou, A. Fu, E. Zhang, MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2, BiochemBiophys Res Commun, 479 (2016) 91-96.

[32] Q.P. Peng, D.B. Du, Q. Ming, F. Hu, Z.B. Wu, S. Qiu, MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D, Cell Mol Biol (Noisy-le-grand), 64 (2018) 62-66.

[33] K.K. Sun, X.J. Shen, D. Yang, M.Q. Gan, G. Liu, Y.F. Zhang, P. Hua, H.D. Wang, X.Y. Wu, MicroRNA-31 triggers G(2)/M cell cycle arrest, enhances the chemosensitivity and inhibits migration and invasion of human gastric cancer cells by downregulating the expression of zestehomolog 2 (ZH2), Arch BiochemBiophys, 663 (2019) 269-275.

[34] C. Lu, Z. Shan, C. Li, L. Yang, MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp, Biomed Pharmacother, 86 (2017) 450-456.

[35] J. Bao, Y. Xu, Q. Wang, J. Zhang, Z. Li, D. Li, J. Li, miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2, Biomed Pharmacother, 92 (2017) 1030-1037.

[36] H. Nie, J. Mu, J. Wang, Y. Li, miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139, Oncol Rep, 40 (2018) 1370-1378.

[37] J. Zou, Y. Xu, MicroRNA-140 Inhibits Cell Proliferation in Gastric Cancer Cell Line HGC-27 by Suppressing SOX4, Med Sci Monit, 22 (2016) 2243-2252.

[38] W. Cao, W. Wei, Z. Zhan, D. Xie, Y. Xie, Q. Xiao, Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis, Int J Mol Med, 41 (2018) 1958-1966.

[39] L. Yang, L. Li, P. Chang, M. Wei, J. Chen, C. Zhu, J. Jia, miR-25 Regulates Gastric Cancer Cell Growth and Apoptosis by Targeting EGR2, Front Genet, 12 (2021) 690196.

[40] H. Guan, W. Li, Y. Li, J. Wang, Y. Li, Y. Tang, S. Lu, MicroRNA-93 promotes proliferation and metastasis of gastric cancer via targeting TIMP2, PLoS One, 12 (2017) e0189490.

[41] T. Jiang, P. Dong, L. Li, X. Ma, P. Xu, H. Zhu, Y. Wang, B. Yang, K. Liu, J. Liu, J. Xue, R. Lv, P. Su, G. Kong, Y. Chang, C. Zhao, L. Wang, MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells, Oncol Rep, 38 (2017) 151-158.

[42] X. Wei, J. Zhu, Y. Zhang, Q. Zhao, H. Wang, K. Gu, miR-338-5p-ZEB2 axis in Diagnostic, Therapeutic Predictive and Prognostic Value of Gastric Cancer, J Cancer, 12 (2021) 6756-6772.

[43] G.A. Calin, C.M. Croce, MicroRNA signatures in human cancers, Nat Rev Cancer, 6 (2006) 857-866.

[44] Y. Fang, H. Shen, H. Li, Y. Cao, R. Qin, L. Long, X. Zhu, C. Xie, W. Xu, miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells, Acta BiochimBiophys Sin (Shanghai), 45 (2013) 963-972.

[45] S. Volinia, G.A. Calin, C.G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R.L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C.C. Harris, C.M. Croce, A microRNA expression signature of human solid tumors defines cancer gene targets, Proc Natl Acad Sci U S A, 103 (2006) 2257-2261.

[46] J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B.L. Ebert, R.H. Mak, A.A. Ferrando, J.R. Downing, T. Jacks, H.R. Horvitz, T.R. Golub, MicroRNA expression profiles classify human cancers, Nature, 435 (2005) 834-838.

[47] J. Wang, J. Chen, S. Sen, MicroRNA as Biomarkers and Diagnostics, J Cell Physiol, 231 (2016) 25-30.

[48] L.Y. Bie, N. Li, W.Y. Deng, X.Y. Lu, P. Guo, S.X. Luo, Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen, Onco Targets Ther, 13 (2020) 1705-1715. 

[49] H.W. Cui, W.Y. Han, L.N. Hou, L. Yang, X. Li, X.L. Su, miR-1915-3p inhibits Bcl-2 expression in the development of gastric cancer, Biosci Rep, 39 (2019). 

[50] H. Guo, Y. Wang, Z. Wang, Z. Wang, S. Xue, The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis, Open Med (Wars), 16 (2021) 1386-1394. 

[51] L. Ebrahimi Ghahnavieh, H. Tabatabaeian, Z. Ebrahimi Ghahnavieh, M.A. Honardoost, M. Azadeh, M. MoazeniBistgani, K. Ghaedi, Fluctuating expression of miR-584 in primary and high-grade gastric cancer, BMC Cancer, 20 (2020) 621. 

[52] Z.T. Dai, Y. Xiang, Y.Y. Duan, J. Wang, J.P. Li, H.M. Zhang, C. Cheng, Q. Wang, T.C. Zhang, X.H. Liao, MiR-17-5p and MKL-1 modulate stem cell characteristics of gastric cancer cells, Int J Biol Sci, 17 (2021) 2278-2293. 

[53] F. di Mario, L.G. Cavallaro, Non-invasive tests in gastric diseases, Dig Liver Dis, 40 (2008) 523-530. 

[54] H.S. Liu, H.S. Xiao, MicroRNAs as potential biomarkers for gastric cancer, World J Gastroenterol, 20 (2014) 12007-12017. 

[55] R.I. Aqeilan, G.A. Calin, C.M. Croce, miR-15a and miR-16-1 in cancer: discovery, function and future perspectives, Cell Death Differ, 17 (2010) 215-220. 

[56] S. Naidu, P. Magee, M. Garofalo, MiRNA-based therapeutic intervention of cancer, J Hematol Oncol, 8 (2015) 68.

How to cite this paper

Research Progress on the Role of miRNAs in the Development of Gastric Cancer

How to cite this paper: Wenjun Jiang, Ya Li. (2023) Research Progress on the Role of miRNAs in the Development of Gastric Cancer. International Journal of Clinical and Experimental Medicine Research, 7(2), 158-162.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.04.011

Home　|　Journals　|　Books　|　For Authors and Reviewers　|　Online Submission　|　Contact Us　|　About Us

Copyright © 2025 Hill Publishing Group Inc. All Rights Reserved.